Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

被引：0
|
作者：
Moa Lugner
Naveed Sattar
Mervete Miftaraj
Jan Ekelund
Stefan Franzén
Ann-Marie Svensson
Björn Eliasson
机构：
[1] University of Gothenburg,Institute of Medicine
[2] Sahlgrenska University Hospital,Institute of Cardiovascular and Medical Sciences
[3] University of Glasgow,undefined
[4] National Diabetes Register,undefined
[5] Centre of Registers,undefined
来源：
Cardiovascular Diabetology | / 20卷
关键词：
Type 2 diabetes; Epidemiology; Sodium glucose transporter 2 inhibitors; Glucagon‐like peptide-1 receptor agonist; Mortality; Cardiovascular disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [32] Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    Bonaventura, A.
    Carbone, S.
    Dixon, D. L.
    Abbate, A.
    Montecucco, F.
    JOURNAL OF INTERNAL MEDICINE, 2019, 286 (01) : 16 - 31
  • [33] Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
    Singh, Awadhesh Kumar
    Shah, Viral N.
    CLINICAL DIABETOLOGY, 2022, 11 (04): : 215 - 221
  • [34] Efficacy of GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Azhie, A.
    Gupta, S.
    Misra, S.
    Chen, S.
    Meerasa, A.
    Dash, S.
    Woo, M.
    Bhat, M.
    TRANSPLANTATION, 2022, 106 (8S) : 103 - 103
  • [35] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [36] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Zengguang Kuang
    Ningning Hou
    Chengxia Kan
    Fang Han
    Hongyan Qiu
    Xiaodong Sun
    International Urology and Nephrology, 2023, 55 : 617 - 629
  • [37] Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis
    Wu, Yaping
    Yang, Zhenxing
    Cao, Qingqing
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (11): : 6852 - 6866
  • [38] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Kuang, Zengguang
    Hou, Ningning
    Kan, Chengxia
    Han, Fang
    Qiu, Hongyan
    Sun, Xiaodong
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (03) : 617 - 629
  • [39] Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study
    Chang, Kai-Cheng
    Kuo, Fan-Chi
    Yang, Chen-Yi
    Yang, Chun-Ting
    Ou, Huang-Tz
    Kuo, Shihchen
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [40] GLP-1 receptor agonists for type 2 diabetes
    De Block, Christophe E. M.
    Van Gaal, Luc F.
    LANCET, 2009, 374 (9683): : 4 - 6
12345